OncoMatch/Clinical Trials/NCT06633601
MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Chest-Wall and Locally Advanced Breast Cancer
Is NCT06633601 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including MR-Guided Focused Ultrasound Technology and Definity Suspension for for breast cancer.
Treatment: MR-Guided Focused Ultrasound Technology · Definity Suspension for — The objective of this study is to demonstrate the feasibility of novel Magnetic Resonance Imaging (MRI)-guided ultrasound stimulated microbubble treatment to enhance radiation effects in humans receiving external beam radiotherapy delivered using a LINAC (linear accelerator) radiation therapy device.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB, IIIC, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anthracycline
Patients having received anthracycline or taxane based chemotherapy within the past 5 days
Cannot have received: taxane
Patients having received anthracycline or taxane based chemotherapy within the past 5 days
Lab requirements
Kidney function
Creatinine within normal institutional limits or creatinine clearance >60mL/min/1.73m2 for patients with creatinine levels above institutional upper limit of normal. Severely impaired renal function with estimated glomerular filtration rate < 30ml/min/1.73m2 and/or on dialysis [excluded].
Cardiac function
Severe cardiovascular, cardiac disease or unstable hemodynamics including myocardial infarction within six months, unstable angina, congestive heart failure, cardiac shunts, cardiac arrhythmia and cardiac pacemaker [excluded]. Known QT prolongation (>450ms for men or >470ms for women) with cardiac impairment if ECG is requested as per SOC [excluded]. Contraindication to perflutren including subjects with a family or personal history of QT prolongation or taking concomitant medications known to cause QTc prolongation.
Creatinine within normal institutional limits or creatinine clearance >60mL/min/1.73m2 for patients with creatinine levels above institutional upper limit of normal. Severely impaired renal function with estimated glomerular filtration rate < 30ml/min/1.73m2 and/or on dialysis [excluded]. Severe cardiovascular, neurological, renal or hematological chronic disease [excluded]. Cardiac disease or unstable hemodynamics including myocardial infarction within six months, unstable angina, congestive heart failure, cardiac shunts, cardiac arrhythmia and cardiac pacemaker [excluded]. Known QT prolongation (>450ms for men or >470ms for women) with cardiac impairment if ECG is requested as per SOC [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify